Novel therapies for relapsed/refractory mantle cell lymphoma, Best Pract Res Clin Haematol, vol.31, issue.1, pp.105-113, 2018. ,
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib, Cancer Cell, vol.32, issue.6, pp.761-776, 2017. ,
Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer, Cancer Res, vol.73, issue.8, 2013. ,
A Phase I Trial of Ibrutinib Plus Palbociclib in Previously Treated Mantle Cell Lymphoma, Blood, vol.133, issue.11, pp.1201-1204, 2019. ,
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, vol.17, issue.4, pp.1244-1253, 1999. ,
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma, J Clin Oncol, vol.24, issue.30, pp.4867-4874, 2006. ,
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, J Clin Oncol, vol.31, issue.29, pp.3688-3695, 2013. ,
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study, Leukemia, vol.32, issue.8, pp.1799-1803, 2018. ,
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial, Lancet, vol.391, pp.659-667, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01726196
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013. ,
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma, Nat Commun, vol.8, p.14920, 2017. ,
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma, N Engl J Med, vol.378, issue.13, pp.1211-1223, 2018. ,
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, issue.9, pp.1022-1035, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02490276
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor ,